drugset / Trial / NCT01550367
Study of Hydroxychloroquine and Aldesleukin in Renal Cell Carcinoma Patients (RCC)
NaSingle-groupOpen-labelTreatment
Summary
The main goal of the research study is to determine whether treating renal cell cancer patients with the study drug, hydroxychloroquine, along with IL-2, a standard treatment of kidney cancer that has spread to other parts of the body, can make the cancer easier to kill and eliminate. Another goal is to see how the study drug affects the body's immune cells which fight cancer cells.
Timeline
- Start
- 2012-03
- Primary completion
- 2018-02-06
- Completion
- 2019-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxychloroquine | Small molecule | 600 mg | Oral |
| Background | aldesleukin | Protein / enzyme biologic | 600000 iu/kg | Intravenous |